Meropenem: Current perspective
Keywords:
Carbapenem, meropenem, drug resistant enterobacteriaceae (DRE)Abstract
Meropenem is an ultra broad spectrum parenteral carbapenem with excellent safety profile and minimal drug interactions. It is effective in a variety of tissue infections. But to prevent emerging drug resistance, its use should be restricted to complicated/serious infections not amenable to other antimicrobials .
References
Craig WA. The Pharmacology of Meropenem: A New Carbapenem Antibiotic. Clinical Infectious Diseases 1997; 24(Suppl 2):S266-75.
Lowe MN, Lamb HM. Meropenem: An Updated Review of its Use in the Management of IntraAbdominal Infections. Drugs 2000 Sep; 60(3):619-646.
Nicolau DP. Pharmacokinetic and Pharmacodynamic Properties of Meropenem. Clinical Infectious Diseases 2008; 47:S32–40.
Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. Carbapenems: past, present and future. Antimicrob Agents Chemother Nov 2011; 55(11): 4943–4960.
Shah D, Narang M. Meropenem: Drug therapy. Indian paediatrics 2004 May; 42:443-45
Gupta E, Mohanty S, Sood S, Dhawan B, Das BK, Kapil A. Emerging resistance to carbapenems in a tertiary care hospital in north India. Indian J Med Res. 2006 July;124: 95-98
Joly-Guillou ML, Kempf M, Cavallo JD, Chomarat M, Dubreuil L, Maugein J, Muller-Serieys C, RousselDelvallez M. Comparative invitro activity of meropenem, imipenem and piperacillin/tazoabctam against 1071 clinical isolates using 2 different methods: a French multicentre study. BMC Infect Dis 2010; 10: 72
Rhomberg PR, Jones RN. Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials. Diagn Microbiol Inect Dis. 2003 Sep;47(1):365-72.
Mohr JF. Update on the Efficacy and Tolerability of Meropenem in the Treatment of Serious Bacterial Infections. Clin Infect Dis. 2008; 47: S41-S51.
Baldwin CM, Lyseng-Williamson KA, Keam SJ. Meropenem: a review of its use in the treatment of serious bacterial infections. Drugs 2008;68(6):803-38.
Norrby SR, Gildon KM. Safety profile of meropenem: a review of nearly 5,000 patients treated with meropenem. Scand J Infect Dis 1999;31(1):3-10.
Linden P. Safety profile of meropenem: an updated review of over 6,000 patients treated with meropenem. Drugs Saf 2007;30(8):657-68.
Cunha BA, Hamid NS, Krol V, Eisentein L. Safety of meropenem in patients reporting penicillin allergy: lack of allergic cross reactions. J Chemother 2008 Apr;20(2):233-7.
Ferrara A, Grassi G, Grassi FA, Piccioni PD, Gialdroni Grassi G. Bactericidal activity of meropenem and interactions with other antibiotics. J Antimicrob Chemother 1989 Sep;24 Suppl A:239-50.
Mori H, Takahashi K, Mizutani T. Interaction between valproic acid and carbapenem antibiotics. Drug Metab Rev 2007;39(4):647-57.
Dauby N, Muylle I, Mouchet F, Sergysels R, Payen MC. Meropenem/clavulanate and linezolid treatment for extensively drug-resistant tuberculosis. Pediatr Infect Dis J 2011 Sep;30(9):812-3.
Bax RP, Bastain W, Featherstone A, Wilkinson DM, Hutchison M, Haworth SJ. The pharmacokinetics of meropenem in volunteers. J Antimicrob Chemother 1989 Sep;24 (Suppl A):311-20.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors contributing to this journal agree to publish their articles under the Creative Commons Attribution 4.0 International License, allowing third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit and that in the event of reuse or distribution, the terms of this license are made clear.
